This phase I study was conducted to determine the dose limiting toxicity, maximum tolerated doses, and recommended phase II doses of the combination of JM-216 and paclitaxel. Patients received paclitaxel intravenously over one hour on day 1 of each cycle. Oral JM-216 was administered on days 1-5 starting after the paclitaxel infusion. Cycles were repeated every 21 days. Patients were accrued at nine different dosing combinations. JM-216 doses ranged from 10-80 mg/m2/day and were combined with paclitaxel doses of 150, 175, or 200 mg/m2. Forty-three patients were treated with 146 cycles of therapy. Dose-limiting toxicity, consisting of febrile neutropenia and grade 3 thrombocytopenia, was encountered in 2 patients at the seventh dose level (JM-216 80 mg/m2/day + paclitaxel 175 mg/m2). Two intermediate dose levels were explored. The first level (JM-216 70 mg/m2/day + paclitaxel 175 mg/m2) produced dose-limiting thrombocytopenia in 1 of 6 patients. However, two additional patients also demonstrated delayed recovery from thrombocytopenia following treatment. As a result, a second intermediate dose level (JM-216 60 mg/m2/day + paclitaxel 200 mg/m2) was filled with six patients. No dose-limiting toxicities were reported in any patients at this dose level. The combination of oral JM-216 and paclitaxel is well-tolerated with minimal non-hematologic and reversible hematologic toxicity. The recommended dose for phase II study is JM-216 60 mg/m2/day for 5 days and paclitaxel 200 mg/m2 on day 1 repeated every 21 days. Higher doses of JM-216 are associated with more severe thrombocytopenia and delayed hematologic recovery resulting in subsequent dosing delays.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.